Real‐world effectiveness and safety of <scp>RC48‐ADC</scp> alone or in combination with <scp>PD</scp>‐1 inhibitors for patients with locally advanced or metastatic urothelial carcinoma: A multicenter, retrospective clinical study

Abstract

Both as monotherapy and in combination with PD-1 inhibitors, RC48-ADC exhibits promising effectiveness and manageable safety profile for mUC patients in real-world settings.